Imricor Medical Systems, Inc. (ASX: IMR) | ARBN 633 106 019 400 Gateway Blvd. | Burnsville, Minnesota 55337 USA | +1 952.818.8400 | imricor.com FDA ACCEPTS IMRICOR’S PMA MANUFACTURING MODULE Key Highlights • The U.S. Food and Drug Administration (FDA) has...
FDA Accepts Imricor PMA Manufacturing Module
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Imricor Medical Systems, Inc. has announced that the FDA has accepted its Premarket Approval manufacturing module, marking a significant milestone in the approval process for its products. The closure of this module indicates that it will not be re-reviewed unless changes are made, bringing Imricor closer to final FDA approval. The FDA will conduct a pre-approval inspection of Imricor's manufacturing sites before any final approval is granted.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Imricor Medical Systems, Inc. on 6ix
Earlier from Imricor Medical Systems
- Release from Voluntary Escrow
- Imricor and Philips Launch Commercial iMR Lab Solution
- Imricor U.S. Commercial Momentum Accelerates
- 1H 2026 Investor Presentation
- 2026 Q2 Form 10-Q
Later from Imricor Medical Systems
- S&P DJI Announces September 2026 Quarterly Rebalance
- Application for quotation of securities - IMR
- Cleansing Notice
- FDA Completes Review of Third PMA Module
- Notification regarding unquoted securities - IMR
Follow Imricor Medical Systems into a list and get an email when it puts out news.
Follow Imricor Medical Systems